Skip to content
2000
Volume 25, Issue 5
  • ISSN: 1871-5265
  • E-ISSN: 2212-3989

Abstract

Ulcerative colitis is a chronic, idiopathic, inflammatory condition affecting the colon, primarily impacting individuals aged 30 to 40. It typically begins in the rectum and gradually progresses to the proximal regions of the colon, characterized by recurrent and remitting mucosal inflammation. Ulcerative colitis is categorized under inflammatory bowel disease, which encompasses various gastrointestinal tract disorders, but its underlying pathophysiology remains unclear. The development of ulcerative colitis is influenced by a combination of genetic, environmental, and inflammatory factors. The severity of the disease guides the management of ulcerative colitis. Restorative strategies include the use of TNF-α (anti-tumor necrosis factor-alpha) monoclonal antibodies. Janus Kinase inhibitors suppress cell signaling of the innate immune system. As ongoing research continues, the treatment options for ulcerative colitis are continually evolving and improving. Various types of dosage forms (tablets, capsules, suppositories, .) are available in the market for managing ulcerative colitis, with the primary goal of achieving and maintaining clinical and endoscopic remission of the disease. Ensuring a high level of patient compliance is crucial when considering the formulation of these dosage forms. This review article seeks to offer a comprehensive understanding of ulcerative colitis while highlighting the existing treatment options on various available dosage forms.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/iddt/10.2174/0118715265315472241029110236
2024-12-20
2025-10-29

  • From This Site

    /content/journals/iddt/10.2174/0118715265315472241029110236
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ChangJ.T. Pathophysiology of inflammatory bowel diseases.N. Engl. J. Med.2020383272652266410.1056/NEJMra2002697 33382932
     [Google Scholar]
  2. GajendranM. LoganathanP. JimenezG. A comprehensive review and update on ulcerative colitis.Dis. Mon.2019651210085110.1016/j.disamonth.2019.02.004 30837080
     [Google Scholar]
  3. FerrettiF. CannatelliR. MonicoM.C. MaconiG. ArdizzoneS. An update on current pharmacotherapeutic options for the treatment of ulcerative colitis.J. Clin. Med.2022119230210.3390/jcm11092302 35566428
     [Google Scholar]
  4. AnanthakrishnanA.N. OxfordE.C. NguyenD.D. SaukJ. YajnikV. XavierR.J. Genetic risk factors for Clostridium difficile infection in ulcerative colitis.Aliment. Pharmacol. Ther.201338552253010.1111/apt.12425 23848254
     [Google Scholar]
  5. DaneseS. FiocchiC. Medical progress.N. Engl. J. Med.1713201136525
     [Google Scholar]
  6. UngaroR. MehandruS. AllenP.B. Peyrin-BirouletL. ColombelJ.F. Ulcerative colitis.Lancet2017389100801756177010.1016/S0140‑6736(16)32126‑2 27914657
     [Google Scholar]
  7. AmarapurkarA.D. AmarapurkarD.N. RathiP. Risk factors for inflammatory bowel disease: A prospective multi-center study.Indian J. Gastroenterol.201837318919510.1007/s12664‑018‑0850‑0 29987750
     [Google Scholar]
  8. Tatiya-aphiradeeN. ChatuphonprasertW. JarukamjornK. Immune response and inflammatory pathway of ulcerative colitis.J. Basic Clin. Physiol. Pharmacol.201830111010.1515/jbcpp‑2018‑0036 30063466
     [Google Scholar]
  9. BernsteinC.N. EliakimA. FedailS. World gastroenterology organisation global guidelines inflammatory bowel disease: update August 2015.J. Clin. Gastroenterol.2016501080381810.1097/MCG.0000000000000660 27741097
     [Google Scholar]
  10. OrdásI. EckmannL. TalaminiM. BaumgartD.C. SandbornW.J. Ulcerative colitis.Lancet201238098531606161910.1016/S0140‑6736(12)60150‑0 22914296
     [Google Scholar]
  11. DuL. HaC. Epidemiology and pathogenesis of ulcerative colitis.Gastroenterol. Clin. North Am.202049464365410.1016/j.gtc.2020.07.005 33121686
     [Google Scholar]
  12. FordA.C. MoayyediP. HanauerS.B. Ulcerative colitis.BMJ2013346252f43210.1136/bmj.f432
     [Google Scholar]
  13. GracieD. FordA. IBS-like symptoms in patients with ulcerative colitis.Clin. Exp. Gastroenterol.2015810110910.2147/CEG.S58153 25733921
     [Google Scholar]
  14. HenriksenM. HøivikM.L. Jelsness-JørgensenL.P. MoumB. Irritable bowel-like symptoms in ulcerative colitis are as common in patients in deep remission as in inflammation: Results from a population-based study.J. Crohn’s Colitis201812438939310.1093/ecco‑jcc/jjx152 29186372
     [Google Scholar]
  15. FellJ.M. MuhammedR. SprayC. CrookK. RussellR.K. Management of ulcerative colitis.Arch. Dis. Child.2016101546947410.1136/archdischild‑2014‑307218 26553909
     [Google Scholar]
  16. MeierJ. SturmA. Current treatment of ulcerative colitis.World J. Gastroenterol.2011172732043212 21912469
     [Google Scholar]
  17. MarshallJ.K. ThabaneM. SteinhartA.H. NewmanJ.R. AnandA. IrvineE.J. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.Cochrane Libr.201211CD00411810.1002/14651858.CD004118.pub2 23152224
     [Google Scholar]
  18. NakaseH. Acute severe ulcerative colitis: Optimal strategies for drug therapy.Gut Liver2023171495710.5009/gnl220017 36375793
     [Google Scholar]
  19. FauselR. AfzaliA. Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists.Ther. Clin. Risk Manag.2015116373 25609972
     [Google Scholar]
  20. HolubarS.D. LightnerA.L. PoylinV. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the surgical management of ulcerative colitis.Dis. Colon Rectum202164778380410.1097/DCR.0000000000002037 33853087
     [Google Scholar]
  21. DevarajB. KaiserA.M. Surgical management of ulcerative colitis in the era of biologicals.Inflamm. Bowel Dis.201521120822010.1097/MIB.0000000000000178 25222665
     [Google Scholar]
  22. GrucelaA. SteinhagenR.M. Current surgical management of ulcerative colitis.Mt. Sinai J. Med.200976660661210.1002/msj.20152 20014421
     [Google Scholar]
  23. McGuireB.B. BranniganA.E. O’ConnellP.R. Ileal pouch–anal anastomosis.Br. J. Surg.200794781282310.1002/bjs.5866 17571291
     [Google Scholar]
  24. CarcamoL. MirandaP. ZúñigaA. Ileal pouch–anal anastomosis in ulcerative colitis: outcomes, functional results, and quality of life in patients with more than 10-year follow-up.Int. J. Colorectal Dis.202035474775310.1007/s00384‑020‑03529‑7 32067061
     [Google Scholar]
  25. MichelassiF. LeeJ. RubinM. Long-term functional results after ileal pouch anal restorative proctocolectomy for ulcerative colitis: a prospective observational study.Ann. Surg.2003238343344510.1097/01.sla.0000086658.60555.ea 14501509
     [Google Scholar]
  26. DeputyM. WorleyG. PatelK. Long‐term outcome and quality of life after continent ileostomy for ulcerative colitis: A systematic review.Colorectal Dis.20212392286229910.1111/codi.15788 34166559
     [Google Scholar]
  27. PineJ. StevensonL. Ileostomy and colostomy.Surgery201432421221710.1016/j.mpsur.2014.01.007
     [Google Scholar]
  28. Cosala. 2014. Available from: https://www.netmeds.com/prescriptions/cosala-400mg-tablet-10s (accessed on 8-10-2024)
  29. Mesahenz. 2014. Available from: https://pharmeasy.in/online-medicine-order/mesahenz-400mg-strip-of- (accessed on 8-10-2024)
  30. Budez. 2014. Available from: https://www.netmeds.com/prescriptions/budez-od-tablet-15s (accessed on 8-10-2024)
  31. Pantocid. 2014. Available from: https://www.netmeds.com/prescriptions/pantocid-l-capsule-10-s(accessed on 8-10-2024)
  32. Mesacol Suppository. 2014. Available from: https://www.myupchar.com/en/medicine/mesacol-p37088904/suppository-v141247 (accessed on 8-10-2024)
  33. Pentasa. 2014. Available from: https://www.apollopharmacy.in/medicine/pentasa-sachet-1gm (accessed on 8-10-2024)
  34. Mesacol Enema. 2014. Available from: https://www.practo.com/medicine-info/mesacol-4-g-liquid-37951(accessed on 8-10-2024)
  35. Pentasa. 2014. Available from: https://pharmeasy.in/online-medicine-order/pentasa-1g-sachet-of-1-granules-10594 (accessed on 8-10-2024).
  36. Vegaz. 2014. Available from: https://www.netmeds.com/prescriptions/vegaz-od-sachet-1gm (accessed on 8-10-2024)
  37. Rowasa. 2014. Available from: https://pharmeasy.in/online-medicine-order/rowasa-1gm-sach-785 (accessed on 8-10-2024)
  38. Entofoam. 2014. Available from: https://www.apollopharmacy.in/medicine/entofoam-10-foam-20-8-gm (accessed on 8-10-2024)
  39. Biologics for ulcerative colitis. Available from: https://www.medicalnewstoday.com/articles/biologics-for-ulcerative-colitis#anti-tnf-agents(accessed on 8-10-2024)
  40. SandbornW.J. KorzenikJ. LashnerB. Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice- daily dosing for maintenance of remission of ulcerative colitis.Gastroenterology201013841286129610.1053/j.gastro.2009.12.054
     [Google Scholar]
  41. BöhmS. KruisW. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Clin. Exp. Gastroenterol.2014736938310.2147/CEG.S35691 25285021
     [Google Scholar]
  42. SandbornW.J. TravisS. MoroL. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.Gastroenterology2012143512181226.e210.1053/j.gastro.2012.08.003 22892337
     [Google Scholar]
  43. KornbluthA. Budesonide extended-release in patients with mild to moderate ulcerative colitis.Gastroenterol. Hepatol. (N. Y.)20151115658 27099573
     [Google Scholar]
  44. GarebB. DijkstraG. KosterinkJ.G.W. FrijlinkH.W. Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice.Int. J. Pharm.201955436637510.1016/j.ijpharm.2018.11.019 30414898
     [Google Scholar]
  45. LichtensteinG.R. HeimansonZ. BosworthB.P. P148 lack of influence of elderly age and gender on the safety profile of budesonide extended-release tablets for ulcerative colitis: A pooled analysis of two randomized, double-blind, phase 3 trials.Inflamm. Bowel Dis.201824S1Suppl. 1S5410.1093/ibd/izy037.018
     [Google Scholar]
  46. BalkrishnaA. SinghR. GohelV. Enteric-coated cologrit tablet exhibit robust antiinflammatory response in ulcerative colitis-like in-vitro models by attuning NFκb-centric signaling axis.Pharmaceuticals (Basel)20221616310.3390/ph16010063 36678560
     [Google Scholar]
  47. BeheraJ. MohantyB. RamaniY.R. RathB. PradhanS. Effect of aqueous extract of Aegle marmelos unripe fruit on inflammatory bowel disease.Indian J. Pharmacol.201244561461810.4103/0253‑7613.100389 23112424
     [Google Scholar]
  48. BadgujarS.B. PatelV.V. BandivdekarA.H. Foeniculum vulgare Mill: a review of its botany, phytochemistry, pharmacology, contemporary application, and toxicology.BioMed Res. Int.2014201413210.1155/2014/842674 25162032
     [Google Scholar]
  49. DeshmukhR. HarwanshR.K. PaulS.D. ShuklaR. Controlled release of sulfasalazine loaded amidated pectin microparticles through Eudragit S 100 coated capsule for management of inflammatory bowel disease.J. Drug Deliv. Sci. Technol.20205510149510.1016/j.jddst.2019.101495
     [Google Scholar]
  50. KediaS. AhujaV. Epidemiology of inflammatory bowel disease in India: The great shift east.Inflamm. Intest. Dis.20172210211510.1159/000465522 30018961
     [Google Scholar]
  51. JakateA. McNameeB. BurkindineD. Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers.Clin. Pharmacol.2019119310110.2147/CPAA.S193191 31372067
     [Google Scholar]
  52. AfzaliA. WheatC.L. LeeS.D. Oral and parenteral corticosteroid therapy in ulcerative colitis.Medical Therapy of Ulcerative Colitis.Springer201411111910.1007/978‑1‑4939‑1677‑1_9
     [Google Scholar]
  53. XuC.T. MengS.Y. PanB.R. Drug therapy for ulcerative colitis.World J. Gastroenterol.200410162311231710.3748/wjg.v10.i16.2311 15285010
     [Google Scholar]
  54. FeuersteinJ.D. CheifetzA.S. Ulcerative Colitis.Mayo Clin. Proc.201489111553156310.1016/j.mayocp.2014.07.002 25199861
     [Google Scholar]
  55. YamamotoS. NakaseH. MikamiS. Long‐term effect of tacrolimus therapy in patients with refractory ulcerative colitis.Aliment. Pharmacol. Ther.200828558959710.1111/j.1365‑2036.2008.03764.x 18549460
     [Google Scholar]
  56. BroadheadJ. GibsonM. Parenteral dosage forms.Pharmaceutical Preformulation and formulation.CRC Press2016337359
     [Google Scholar]
  57. DornblaserE.K. WayS.L. BrazeauG.A. Dosage forms: parenterals.In encyclopedia of pharmaceutical science and technology.CRC Press2013884897
     [Google Scholar]
  58. ShimizuH. FujiiT. KinoshitaK. Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus.BMC Gastroenterol.202121149410.1186/s12876‑021‑02043‑6 34949172
     [Google Scholar]
  59. MatsuokaK. SaitoE. FujiiT. Nagahori, M.; Ohtsuka, K.; Watanabe, M. Tacrolimus for the treatment of ulcerative colitis.Intest. Res.201513321922610.5217/ir.2015.13.3.219 26130996
     [Google Scholar]
  60. CohenR.D. WeisshofR. A comprehensive review of topical therapies for distal ulcerative colitis.Gastroenterol. Hepatol. (N. Y.)20201612127 33867885
     [Google Scholar]
  61. HanauerS.B. Oral or topical 5-ASA in ulcerative colitis.Dig. Dis.2016341-212212410.1159/000443026 26982709
     [Google Scholar]
  62. CrispinoP. PicaR. UnimH. Efficacy of mesalazine or beclomethasone dipropionate enema or their combination in patients with distal active ulcerative colitis.Eur. Rev. Med. Pharmacol. Sci.2015191528302837 26241537
     [Google Scholar]
  63. LevineA. YerushalmiB. KoriM. Mesalamine enemas for induction of remission in oral mesalamine-refractory pediatric ulcerative colitis: A prospective cohort study.J. Crohn’s Colitis201711897097410.1093/ecco‑jcc/jjx042 28369299
     [Google Scholar]
  64. ChibbarR. MossA.C. Mesalamine in the initial therapy of ulcerative colitis.Gastroenterol. Clin. North Am.202049468970410.1016/j.gtc.2020.07.002 33121689
     [Google Scholar]
  65. BřezinaJ. BajerL. WohlP. Fecal microbial transplantation versus mesalamine enema for treatment of active left-sided ulcerative colitis—Results of a randomized controlled trial.J. Clin. Med.20211013275310.3390/jcm10132753 34206663
     [Google Scholar]
  66. BaviskarP. BedseA. SadiqueS. KundeV. JaiswalS. Drug delivery on rectal absorption: Suppositories.Int. J. Pharm. Sci. Rev. Res.20132117076
     [Google Scholar]
  67. KruisW. NeshtaV. PesegovaM. Budesonide suppositories are effective and safe for treating acute ulcerative proctitis.Clin. Gastroenterol. Hepatol.201917198106.e410.1016/j.cgh.2018.04.027 29702300
     [Google Scholar]
  68. WatanabeM. NishinoH. SameshimaY. OtaA. NakamuraS. HibiT. Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - a placebo-controlled study.Aliment. Pharmacol. Ther.201338326427310.1111/apt.12362 23734840
     [Google Scholar]
  69. HeymanM.B. KierkusJ. SpénardJ. ShbakloH. GiguereM. Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.Inflamm. Bowel Dis.201016111931193910.1002/ibd.21256 20848454
     [Google Scholar]
  70. HarrisM.S. LichtensteinG.R. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.Aliment. Pharmacol. Ther.2011339996100910.1111/j.1365‑2036.2011.04619.x 21385194
     [Google Scholar]
  71. KaurA. GoggolidouP. Ulcerative colitis: understanding its cellular pathology could provide insights into novel therapies.J. Inflamm. (Lond.)20201711510.1186/s12950‑020‑00246‑4 32336953
     [Google Scholar]
  72. AwadA. HollisE. GoyanesA. OrluM. GaisfordS. BasitA.W. 3D printed multi-drug-loaded suppositories for acute severe ulcerative colitis.Int. J. Pharm. X2023510016510.1016/j.ijpx.2023.100165 36876053
     [Google Scholar]
  73. Seoane-ViañoI. OngJ.J. Luzardo-ÁlvarezA. 3D printed tacrolimus suppositories for the treatment of ulcerative colitis.Asian J. Pharm. Sci.202116111011910.1016/j.ajps.2020.06.003 33613734
     [Google Scholar]
  74. WeiM. LiuD. SunY. XieH. DuL. JinY. Mesalazine hollow suppositories based on 3D printing for treatment of ulcerative colitis.Int. J. Pharm.202364212319610.1016/j.ijpharm.2023.123196 37399930
     [Google Scholar]
  75. AhmadJ. GargA. MustafaG. MohammedA.A. AhmadM.Z. 3D printing technology as a promising tool to design nanomedicine- based solid dosage forms: Contemporary research and future scope.Pharmaceutics2023155144810.3390/pharmaceutics15051448 37242690
     [Google Scholar]
  76. LeifeldL. PfützerR. MorgensternJ. Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.Aliment. Pharmacol. Ther.20113491115112210.1111/j.1365‑2036.2011.04840.x 21923715
     [Google Scholar]
  77. LichtensteinG.R. GordonG.L. ZakkoS. Clinical trial: once‐daily mesalamine granules for maintenance of remission of ulcerative colitis – a 6‐month placebo‐controlled trial.Aliment. Pharmacol. Ther.201032899099910.1111/j.1365‑2036.2010.04438.x 20937044
     [Google Scholar]
  78. ZakkoS.F. GordonG.L. MurthyU. Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.Postgrad. Med.2016128327328110.1080/00325481.2016.1152876 26861051
     [Google Scholar]
  79. ConstantB.D. BaldassanoR. KirschJ. MitchelE.B. SteinR. AlbenbergL. Tofacitinib salvage therapy for children hospitalized for corticosteroid-and biologic-refractory ulcerative colitis.J. Pediatr. Gastroenterol. Nutr.202275672473010.1097/MPG.0000000000003616 36122389
     [Google Scholar]
  80. DubinskyM. BleakmanA.P. PanaccioneR. Bowel urgency in ulcerative colitis: current perspectives and future directions.Am. J. Gastroenterol.2023118111940195310.14309/ajg.0000000000002404 37436151
     [Google Scholar]
  81. DubinskyM.C. IrvingP.M. PanaccioneR. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults.J. Patient. Rep. Outcomes2022613110.1186/s41687‑022‑00439‑w 35362902
     [Google Scholar]
  82. GreenJ.R.B. SwanC.H.J. GibsonJ.A. KerrG.D. SwarbrickE.T. ThorntonP.C. Patient‐led variable dosing with balsalazide as long‐term therapy for maintenance in ulcerative colitis: a 3‐year prospective observational study.Aliment. Pharmacol. Ther.200419443544210.1111/j.1365‑2036.2004.01866.x 14871283
     [Google Scholar]
  83. SegalJ.P. LeBlancJ.F. HartA.L. Ulcerative colitis: an update.Clin. Med. (Lond.)202121213513910.7861/clinmed.2021‑0080 33762374
     [Google Scholar]
  84. YangL.S. PerryE. ShanL. Clinical application and diagnostic accuracy of artificial intelligence in colonoscopy for inflammatory bowel disease: systematic review.Endosc. Int. Open2022107E1004E101310.1055/a‑1846‑0642 35845028
     [Google Scholar]
  85. UchikovP. KhalidU. VankovN. The role of artificial intelligence in the diagnosis and treatment of ulcerative colitis.Diagnostics (Basel)20241410100410.3390/diagnostics14101004 38786302
     [Google Scholar]
  86. ChangY. WangZ. SunH.B. LiY.Q. TangT.Y. Artificial intelligence in inflammatory bowel disease endoscopy: advanced development and new horizons.Gastroenterol. Res. Pract.202320231710.1155/2023/3228832 37101782
     [Google Scholar]
  87. DaneseS. Artificial intelligence in endoscopic assessment of ulcerative colitis: virtual painting with PICaSSO.Endoscopy202355434234310.1055/a‑1986‑7532 36630973
     [Google Scholar]
  88. CannatelliR. ParigiT.L. IacucciM. A virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic activity/remission and predict clinical outcomes in ulcerative colitis.Endoscopy202355433234110.1055/a‑1960‑3645 36228649
     [Google Scholar]
  89. MaedaY. KudoS. OgataN. Can artificial intelligence help to detect dysplasia in patients with ulcerative colitis?Endoscopy2021537E273E27410.1055/a‑1261‑2944 33003217
     [Google Scholar]
  90. BaikS.H. KimW.H. A comprehensive review of inflammatory bowel disease focusing on surgical management.J. Korean Soc. Coloproctol.201228312113110.3393/jksc.2012.28.3.121 22816055
     [Google Scholar]
  91. BhambhvaniH.P. ZamoraA. Deep learning enabled classification of Mayo endoscopic subscore in patients with ulcerative colitis.Eur. J. Gastroenterol. Hepatol.202133564564910.1097/MEG.0000000000001952 33079775
     [Google Scholar]
  92. ChhibbaT. WongE.C.L. ReinischW. TargownikL. NarulaN. Comparing the efficacy of vedolizumab between males and females: a post-hoc analysis of GEMINI-1 and VARSITY.Eur. J. Gastroenterol. Hepatol.202436670471110.1097/MEG.0000000000002759 38526945
     [Google Scholar]
  93. MichalopoulosG. KarmirisK. When disease extent is not always a key parameter: Management of refractory ulcerative proctitis.Curr. Res. Pharmacol. Drug Discov.2022310007110.1016/j.crphar.2021.100071 34988432
     [Google Scholar]
  94. RegueiroM. LoftusE.V.Jr SteinhartH.A. CohenR.D. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: Summary statement.Inflamm. Bowel Dis.2006121097297810.1097/01.mib.0000231496.92013.85 17012968
     [Google Scholar]
  95. Tamir-DegabliN. MaharshakN. CohenN.A. Salvage therapy in acute severe ulcerative colitis: current practice and a look to the future.Turk. J. Gastroenterol.202334657658310.5152/tjg.2023.23103 37303244
     [Google Scholar]
  96. Vaghari TabariM. MoeinS. QujeqD. Evaluation of the potential antioxidant role of high-density lipoprotein-cholesterol (hdl-c) in patients with ulcerative colitis.Annal Colorectal ResIn Press10.5812/acr.13699
     [Google Scholar]
/content/journals/iddt/10.2174/0118715265315472241029110236
Loading
Current Approaches to Ulcerative Colitis Management: A Comprehensive Overview of Methodologies and Treatments
Infect. Disord. Drug Targets 25, E18715265315472 (2025); https://doi.org/10.2174/0118715265315472241029110236
/content/journals/iddt/10.2174/0118715265315472241029110236
/content/journals/iddt/10.2174/0118715265315472241029110236
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): capsules; interleukins; janus kinase; suppositories; tablets; tumor necrosis factor; Ulcerative colitis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test